US Stock MarketDetailed Quotes

AKBA Akebia Therapeutics

Watchlist

1.8500
+0.0200+1.09%

Close Feb 28 16:00 ET

1.8393
-0.0107-0.58%

Pre 08:46 ET

403.64MMarket Cap-8.41P/E (TTM)

Akebia Therapeutics Stock Forum

101674396

Feb 20 08:34

$Akebia Therapeutics (AKBA.US)$ ..What happen?

101674396

Feb 18 09:13

$Akebia Therapeutics (AKBA.US)$ hold or sell?

101674396

Jan 29 08:54

$Akebia Therapeutics (AKBA.US)$ chance to hit 4plus ? my avg cost 3.50

小竜

Jan 28 09:39

$Akebia Therapeutics (AKBA.US)$ topping up

Jaguar8

Jan 21 23:03

🟢 Watchlist, JANUARY 22,2025, Wednesday. NFA

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards ...

小竜

Jan 21 09:34

$Akebia Therapeutics (AKBA.US)$ 👇👇👇 double bottom. Today is breakout day

小竜: $Akebia Therapeutics (AKBA.US)$ Double bottom 👌 i get it.

小竜

Jan 21 09:33

$Akebia Therapeutics (AKBA.US)$ thhis is it.

101674396

Jan 13 09:43

$Akebia Therapeutics (AKBA.US)$ ..Don’t sell!! hold

Jaguar8

Jan 13 07:37

NEWS

$Akebia Therapeutics (AKBA.US)$
Akebia Therapeutics Announces Multiple Positive Business Updates
Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. The company has secured commercial supply contracts covering nearly 100% of U.S. dialysis patients and commenced product shipments in January 2025.
Market research indicates strong physician interest, with 99% of n...

Trytosaveabit

Jan 13 07:29

Update

$Akebia Therapeutics (AKBA.US)$ Akebia Announced Near 100% U.S. Dialysis Coverage For Vafseo, Vafseo Shipments Commence, Phase 3 Trial For Late-Stage Non-Dialysis CKD Patients Planned for Mid-2025
Benzinga· 2 mins ago
New Commercial Supply Contracts for Vafseo (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S.
Vafseo tablets now shipping in the U.S.
Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo...

No comment yet

AKBA Akebia Therapeutics

Akebia Therapeutics Stock Forum

Trending Stocks